Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease

Parion Sciences

Status and phase

Completed

Phase 1

Conditions

Dry Eye Disease

Treatments

Drug: P-321 Ophthalmic Solution placebo

Drug: P-321 Ophthalmic Solution

Study type

Interventional

Funder types

Industry

Identifiers

NCT02242032

P-321-101

Details and patient eligibility

About

The purpose of this study is to assess the safety and tolerability of P-321 Ophthalmic Solution in subjects with mild to moderate dry eye disease.

Full description

This is a single-center, dose escalation, randomized, double-masked, placebo-controlled, Phase 1/2a trial designed to evaluate the safety and tolerability of P-321 Ophthalmic Solution in subjects with mild to moderate dry eye for up to 4-weeks of treatment and up to 8 scheduled in clinic visits. This study will conduct a consecutive dose escalation of the following concentrations of P-321 Ophthalmic Solution given two times a day via ocular instillation: 0.0005% (Cohort 1), 0.0015% (Cohort 2), 0.005% (Cohort 3), and 0.01% (Cohort 4). Up to 48 subjects will be enrolled in four consecutive cohorts. Subjects will be randomized to P-321 Ophthalmic Solution or placebo in a 3:1 ratio.

Safety and tolerability assessments, drug plasma concentrations and drug urine concentrations will be evaluated throughout the study in all cohorts.

Enrollment

53 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Individuals of both genders and any race will be eligible for study participation if they:
1. Provide written informed consent.
2. Are 18 - 80 years of age.
3. Corneal fluorescein staining score ≥2/15 on the NEI/Industry scale
4. Conjunctival lissamine staining score of ≥ 2/18 on the NEI/Industry scale
5. Schirmer <10mm/5min
6. Are willing and able to follow instructions and can be present for the required study visits for the duration of the study.
7. Female patients of child bearing potential must have a negative urine pregnancy test at Screening and agree to use a medically acceptable form of birth control. Male subjects who are sexually active must be willing to use highly effective contraception (i.e., less than 1% failure rate) during heterosexual intercourse from Day 1 through completion of the study.
8. Have a history of Dry Eye Disease in both eyes supported by a previous clinical diagnosis or have a self-reported history of subjective complaints for at least 4 months prior to Screening, low tear volume, and ocular staining.
9. Have documented history of topical lubricants at least daily or the desire to use topical lubricants in the past 4 months.
10. Have normal lid anatomy

Exclusion criteria

Individuals are not eligible for study participation if:
1. Have anterior segment eye disease except primary dry eye.
2. Patients with an identifiable or suspected secondary dry eye, i.e., a documented or likely systemic, ocular, pharmacologic, post-traumatic, post-surgical, or external cause for dry eye symptoms or ocular surface staining.
3. Patients with current punctal plugs, punctal occlusion, or history of nasolacrimal duct obstruction are excluded.
4. Have a history of glaucoma or intraocular pressure (IOP) > 25 mmHg at the Screening Visit (Visit 1) or a history of elevated IOP within the past year prior to Visit 1
5. Contact lenses wear in the previous 30 days or during the Treatment Phase of the study.
6. Use of lid scrubs (including baby shampoos)
7. Known hypersensitivity to the study investigational medicinal product, or formulation excipients, including amiloride or related drugs or allergies to the components of the study drug.
8. Any significant chronic illness that, in the opinion of the Principal Investigator (PI), could interfere with the study parameters.
9. Use of any investigational product or device within 30 days prior to the Screening Visit or during the study.
10. Those unable in the opinion of the PI to comply fully with the study requirements or complete the study.